Royalty Pharma Raises Guidance A Third Time As Q3 Royalty Growth Slows And Pelacarsen Fails

Royalty Pharma (NASDAQ: RPRX) reported third-quarter earnings of $1.21 per share, 2.5% above the $1.18 consensus and up 3.4% from a year ago. Revenue was $690.0 million, up 13.3% year over year but 21.3% below the $876.39 million consensus. The more important development was guidance. Management raised its full-year 2026 Portfolio Receipts outlook for the third straight quarter, to $3.50 billion to $3.55 billion from $3.40 billion to $3.50 billion. That implies Royalty Receipts growth of 10% to 11%, up from 7% to 10% in August and 3% to 8% at the start of the year. The central tension is that full-year expectations keep rising while quarterly growth is slowing.

The revenue miss needs context. The $690 million figure is GAAP total income and other revenues, which includes accounting income on financial royalty assets. The company's preferred cash metric, Portfolio Receipts, was $890 million, up 9%. The consensus figure sits much closer to that cash number than to the GAAP line, so the headline shortfall appears to reflect a mismatch in measurement basis rather than weaker royalty collections.

The GAAP income statement was noticeably weaker:

• Net income attributable to Royalty Pharma fell to $145 million from $284 million.
• The decline was driven by a $150 million non-cash impairment on pelacarsen.
• A $63 million other expense line replaced $77 million of other income a year ago.

Cash generation also lagged the receipts growth. Net cash from operations slipped 2% to $686 million. Portfolio Cash Flow rose only 2% to $673 million because net interest paid jumped to $167 million from $123 million. On the call, management attributed the drop in the quarter's cash flow margin to about 76%, from roughly 95% in Q2, to the timing of interest payments. The release said fourth-quarter interest paid should be de minimis.

Beneath the 9% Royalty Receipts gain, two very different parts of the portfolio are moving in opposite directions.

*Growth drivers*

• Tremfya rose 61% to $80 million.
• Voranigo rose 65% to $55 million.
• Evrysdi rose 38% to $71 million, helped by additional royalties acquired in December 2025.
• Imdelltra contributed $19 million in its first comparable period.

*Drags*

• Promacta collapsed 75% under U.S. generic competition.
• Imbruvica fell 24%.
• The two together represent roughly a 5-point headwind, per the call.
• The cystic fibrosis franchise, the largest single royalty at $225 million, grew just 1%.

The deceleration in Royalty Receipts growth, from 13% in Q1 and 14% in Q2 to 9% in Q3, is real. However, year-to-date growth of 12% after absorbing that erosion supports the call's argument that the newer growth assets are carrying the portfolio. Leverage also improved:

• Debt leverage fell to 2.7x, from 2.9x in Q1.
• The company repaid a $380 million term loan.
• Return on invested capital edged up to 14.3%.

The pipeline news was busy and mostly favorable. FDA approvals for Revolution Medicines' Rasonque, Teva's Weltruza, Ziihera and Mimrylo added to the commercial base. Amgen's positive first-line maintenance Phase 3 for Imdelltra is notable because Royalty Pharma retains the vast majority of its royalty between $1.5 billion and $2.5 billion in sales. New royalties on Zoryve and Mimrylo, each for $100 million, add approved, growing products. Management reaffirmed its target to meet or exceed $4.7 billion in 2030 receipts.

Bears still have legitimate ammunition:

• Pelacarsen's failure caps the related Spinraza royalty at roughly a 1.1x return.
• It raises read-through questions for the larger Amgen olpasiran exposure.
• Revolution Medicines declined the third royalty funding tranche, limiting upside on daraxonrasib.
• Capital deployment of $1.6 billion year to date trails the $2.6 billion deployed in 2025.
• Management flagged drug-pricing policy uncertainty and rising Chinese competition as broader risks.

Investors arrived at the report already leaning bullish. Earnings Whispers sentiment rose sharply, from 0.30 at the prior report to 0.73. As of the pre-report snapshot, shares were $66.40, up 11.5% since the post-August open. That put them roughly 24.5% above the 200-day moving average and just 1.9% below the $67.71 52-week high set on October 30. Much of that gain came quickly: the stock rallied about 20% off its October 8 low of $55.13. The Earnings Whispers trend signals are uniformly positive. The setup is therefore crowded rather than skeptical. A third guidance raise was likely partly anticipated, and the deceleration plus pelacarsen fallout give a stock trading near its highs less cushion.

The bottom line is that Royalty Pharma's core cash engine is healthier than the GAAP revenue miss and halved net income suggest. Newer assets are more than offsetting Promacta and Imbruvica erosion, and management has now raised full-year guidance three times. Even so, the quarter showed slowing growth, a costly clinical setback with read-through risk, and a capital-deployment pace well below last year's. With sentiment and price near their highs, the burden now shifts to the fourth quarter showing that the 9% print was a trough rather than a new run rate.

Read our earnings preview for Royalty Pharma plc: https://www.earningswhispers.com/article/RPRX/21736

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.